Candriam SCA’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Candriam SCA’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-152,187	Closed	-$572K	–	890
2023 Q1	$572K	Sell	152,187 -223,975	-60%	-$1.04M	﹤0.01%	757
2022 Q4	$1.89M	Buy	376,162 +92,112	+32%	+$577K	0.01%	590
2022 Q3	$3.72M	Buy	284,050 +66,863	+31%	+$1.01M	0.03%	446
2022 Q2	$2.78M	Hold	217,187	–	–	0.02%	432
2022 Q1	$3.31M	Buy	+217,187	New	+$3.39M	0.02%	434
2021 Q4	–	Sell	-564,059	Closed	-$11.9M	–	880
2021 Q3	$11.9M	Hold	564,059	–	–	0.08%	244
2021 Q2	$11.1M	Buy	564,059 +342,425	+155%	+$8.01M	0.08%	272
2021 Q1	$6.45M	Hold	221,634	–	–	0.05%	332
2020 Q4	$6.71M	Sell	221,634 -7,130	-3%	-$156K	0.05%	341
2020 Q3	$3.64M	Hold	228,764	–	–	0.03%	402
2020 Q2	$4.52M	Sell	228,764 -13,236	-5%	-$253K	0.05%	356
2020 Q1	$4.37M	Hold	242,000	–	–	0.05%	385
2019 Q4	$4.47M	Buy	242,000 +87,000	+56%	+$1.27M	0.05%	395
2019 Q3	$2.15M	Buy	155,000 +20,000	+15%	+$300K	0.03%	471
2019 Q2	$1.97M	Buy	+135,000	New	+$1.98M	0.02%	520

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Candriam SCA's NGM Position: Q2 2023 in Review

Candriam SCA sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 152,187 shares — an estimated $572K sold.

Candriam SCA first reported a position in NGM in Q2 2019 and held it in 15 quarters. The position peaked at $11.9M in Q3 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Candriam SCA reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 152,187 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $572K.
Candriam SCA first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 15 quarters.
Candriam SCA's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $11.9M in Q3 2021.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.